Abstract
Diabetes mellitus (DM) is one of global problems in modern endocrinology. This is due to a signifi cant increase in the incidence of this disease over the past decades, the prolongation of patients' lives thanks to the increasingly eff ective modern hypoglycemic therapy, the sedentary and stressful lifestyle of modern Ukrainians. Disorders of the gastrointestinal tract develop and progress already at the time of the patient's diagnosis of DM. It should also be understood that diseases of the digestive system in DM are formed and grow with poor glycemic control of the disease; the presence of obesity, insulin resistance, lipid metabolism disorders and with an increasing DM duration. Among these abnormalities, gastrointestinal changes are distinguished, which are primarily based on diabetic neuropathy (pathology of extra- and intraorganic innervation), damage to the vagus nerve; and conditions associated with hormonal and metabolic changes, which are the result of not only disturbed tissue metabolism, but also pronounced vascular changes. In addition, recent studies prove, that one of equally important factors infl uencing the processes in the gastrointestinal tract and liver is the intestinal microbiota, which covers a wide range of microorganisms. Diabetic hepatopathy is associated primarily with its fatty infi ltration caused by insulin defi ciency, liver glycogen depletion, increased lipolysis in the periphery, mobilization of free fatty acids and triglycerides from adipose tissue and their increased transport to the liver. The development of metabolically associated fatty liver disease also leads to the progression of cardiovascular complications of DM. The presence of gastrointestinal abnormalities in patients with DM requires monitoring by doctors of various specialties. It is extremely important in daily medical practice to take into account the state of the digestive organs when choosing the tactics of both hypoglycemic and any other therapy.
References
Боднар ПМ, Комісаренко ЮІ, Михальчишин ГП, Бобрик МІ, Шуляренко ЛВ, Приступюк ОМ, та ін. Ендокринологія: підручник для студ. вищих мед. навч. закладів. 5-те вид., оновл. та доповн. Вінниця: Нова книга; 2020. 536 с. (Bodnar PM, Komisarenko YuI, Mikhalchyshyn GP, Bobryk MI, Shulyarenko LV, Prystupyuk OM, et al. Endocrinology: textbook for students. higher med. education institutions. 5th edition, updated and additional. Vinnytsia: New book. 2020. 536 p. Ukrainian).
Magliano DJ, Boyko EJ; IDF diabetes atlas 10th edition scientifi c committee. IDF diabetes atlas [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021.
Du YT, Rayner CK, Jones KL, Talley NJ, Horowitz M. Gastrointestinal symptoms in diabetes: prevalence, assessment, pathogenesis, and management. Diabetes Care. 2018 Mar;41(3):627-37. doi: 10.2337/dc17-1536.
Camilleri M. Upper gastrointestinal manifestations of diabetes. In: Vella A, editor. Clinical dilemmas in diabetes, second edition. Wiley-Blackwell; 2021. p. 269-79. doi: 10.1002/9781119603207.ch22.
Leeds JS, Hadjivassiliou M, Tesfaye S, Sanders DS. Lower gastrointestinal symptoms are associated with worse glycemic control and quality of life in type 1 diabetes mellitus. BMJ Open Diabetes Res Care. 2018 May 29;6(1):e000514. doi: 10.1136/bmjdrc-2018-000514.
Asgharnezhad M, Joukar F, Fathalipour M, Khosousi M, Hassanipour S, Pourshams A, et al. Gastrointestinal symptoms in patients with diabetes mellitus and non-diabetic: A crosssectional study in north of Iran. Diabetes Metab Syndr. 2019 May-Jun;13(3):2236-40. doi: 10.1016/j.dsx.2019.05.028.
Hosseininasab Nodoushan SA, Nabavi A. The Interaction of Helicobacter pylori infection and type 2 diabetes mellitus. Adv Biomed Res. 2019 Feb 27;8:15. doi: 10.4103/abr.abr_37_18.
Ha JO, Lee TH, Lee CW, Park JY, Choi SH, Park HS, et al. Prevalence and risk factors of gastroesophageal refl ux disease in patients with type 2 diabetes mellitus. Diabetes Metab J. 2016 Aug;40(4):297-307. doi: 10.4093/dmj.2016.40.4.297.
Lacy BE, Crowell MD, Mathis C, Bauer D, Heinberg LJ. Gastroparesis: quality of life and health care utilization. J Clin Gastroenterol. 2018 Jan;52(1):20-4. doi: 10.1097/MCG.0000000000000728.
Chhabra А, Grover S, Vij A, Singh AP. Gallbladder disease in type-2 diabetes mellitus patients. Int J Med and Dent Sci. 2013;2(1):7-15. doi: 10.18311/ijmds/2013/19815.
Gould M, Sellin JH. Diabetic diarrhea. Curr Gastroenterol Rep. 2009 Oct;11(5):354-9. doi: 10.1007/s11894-009-0054-y.
Meldgaard T, Olesen SS, Farmer AD, Krogh K, Wendel AA, Brock B, et al. Diabetic enteropathy: from molecule to mechanismbased treatment. J Diabetes Res. 2018 Sep 16;2018:3827301. doi: 10.1155/2018/3827301.
Москва ХА, Кіхтяк ОП, Лаповець ЛЄ, Урбанович АМ. Зміни мікробіоти кишківника під впливом метформіну, піоглітазону та левотироксину у пацієнтів з цукровим діабетом 2-го типу, надмірною вагою та гіпотиреозом. Проблеми ендокринної патології. 2022;79(4):45-51 (Moskva KhA, Kikhtyak OP,
Lapovets LY, Urbanovych AM. Changes in the gut microbiota under the infl uence of metformin, pioglitazone, and levothyroxine in overweight patients with type 2 diabetes mellitus and hypothyroidism. Problems of Endocrine Pathology. Ukrainian). doi: 10.21856/j-PEP.2022.4.06.
Боровець МО, Урбанович АМ. Мікробіота та ендокринно-метаболічні захворювання. Діабет Ожиріння Метаболічний синдром. 2020;(1):28-34 (Borovets MO, Urbanovych AM. Microbiota and endocrine-metabolic diseases. Diabetes Obesity Metabolic syndrome. 2020;(1):28-34. Ukrainian).
Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives. Biomolecules. 2021 Dec 31;12(1):56. doi: 10.3390/biom12010056.
